肿瘤标志物和凝血指标在肺癌辅助诊断中的效果分析
|
摘要
目的探析肺癌辅助诊断中肿瘤标志物与凝血指标的诊断价值。方法将2016年2月～2018年11月我院收治的48例肺癌患者纳入研究组,将同期48例健康体检人员纳入对照组,通过电化学发光仪和全自动血凝分析仪检测患者肿瘤标志物和凝血指标,肿瘤标志物包括鳞状细胞癌相关抗原(SCC)、癌胚抗原(CEA)、细胞角蛋白19(CYFRA21-1)和神经元特异性烯醇化酶(NSE);凝血指标包括D-二聚体(D-dimer)、纤维蛋白原(FIB)、活血部分凝血活酶时间(APTT)、凝血酶时间(TT)及血浆凝血酶原时间(PT)。结果在SCC、CYFRA21-1、CEA及NSE方面,研究组均高于对照组,差异存在统计学意义(P<0.05);研究组TT低于对照组,而D-dimer、FIB高于对照组,差异均有统计学意义(P<0.05);两组APTT及PT分别比较,差异均无统计学意义(P>0.05)。结论根据CEA、CYFRA21-1、NSE及FIB指标水平,有助于肺癌疾病诊断准确率的提高,根据肿瘤标志物及凝血指标数值,有助于判断肺癌发展状况。
Objective To investigate the diagnostic value of tumor markers and coagulation parameters in the diagnosis of lung cancer. Methods 48 patients with lung cancer admitted to our hospital from February 2016 to November 2018 were enrolled in the study group. 48 healthysubjects were included in the control group, and the tumor markers were detected by electrochemiluminescence and automatic hemagglutination analyzer. And coagulation indicators, tumor markers including squamous cell carcinoma associated antigen(SCC), carcinoembryonic antigen(CEA), cytokeratin 19(CYFRA21-1) and neuron specific enolase(NSE); coagulation indicators include D-dimer, fibrinogen(FIB), viable partial thromboplastin time(APTT),thrombin time(TT), and plasma prothrombin time(PT). Results In the SCC, CYFRA21-1, CEA and NSE, the study group was higher than the control group, the difference was statistically significant(P<0.05); the study group TT was higher than the control group, and the D-dimer was lower than the control group, the difference All of them were statistically significant(P<0.05). There were no significant differences in APTT and PT between the two groups(P>0.05). Conclusion According to CEA, CYFRA21-1, NSE and FIB levels, it can help to improve the accuracy of lung cancer diagnosis.According to the tumor markers and coagulation index values, it can help to judge the development of lung cancer.
Objective To investigate the diagnostic value of tumor markers and coagulation parameters in the diagnosis of lung cancer. Methods 48 patients with lung cancer admitted to our hospital from February 2016 to November 2018 were enrolled in the study group. 48 healthysubjects were included in the control group, and the tumor markers were detected by electrochemiluminescence and automatic hemagglutination analyzer. And coagulation indicators, tumor markers including squamous cell carcinoma associated antigen(SCC), carcinoembryonic antigen(CEA), cytokeratin 19(CYFRA21-1) and neuron specific enolase(NSE); coagulation indicators include D-dimer, fibrinogen(FIB), viable partial thromboplastin time(APTT),thrombin time(TT), and plasma prothrombin time(PT). Results In the SCC, CYFRA21-1, CEA and NSE, the study group was higher than the control group, the difference was statistically significant(P<0.05); the study group TT was higher than the control group, and the D-dimer was lower than the control group, the difference All of them were statistically significant(P<0.05). There were no significant differences in APTT and PT between the two groups(P>0.05). Conclusion According to CEA, CYFRA21-1, NSE and FIB levels, it can help to improve the accuracy of lung cancer diagnosis.According to the tumor markers and coagulation index values, it can help to judge the development of lung cancer.
引文
[1]吴园园,管世鹤,杨凯,等.血清肿瘤标志物在肺癌辅助诊断中的应用[J].中国微生态学杂志,2017,29(5):547-549.
[2]单新洁,祁晓婷,俞荣.4项血清肿瘤标志物联合检测在肺癌中的应用价值分析[J].河北医科大学学报,2018,39(7):833-837.
[3]张海晨,王浩,宋云霄,等.多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J].检验医学,2018,33(7):590-596.
[4]范润萍,徐笑红.NLR、LDH结合几种常见肿瘤标志物在肺癌诊断中的价值[J].中国医师杂志,2017,19(6):895-898.
[5]舒媚,吴振兴,朱振亮,等.血清肿瘤标志物联合检测在肺癌诊断中的价值[J].中华全科医学,2016,14(6):1019-1021.
[6]余洲海,孟伟.联合检测血清中四种肿瘤标志物对肺癌的诊断价值评估[J].标记免疫分析与临床,2016,23(6):655-658.
[7]刘俊,孙璀.血清肿瘤标志物单独或联合检测在原发性肺癌中的诊断价值[J].检验医学与临床,2017,14(19):2887-2889.
[8]徐一凯,陈素珍,胡丹丹,等.肿瘤标志物神经特异性烯醇化酶与糖链抗原125及血清细胞角蛋白19片段和癌胚抗原在肺癌诊断与分期中的价值[J].中国临床保健杂志,2017,20(5):498-501.
[9]杨含,罗素霞.六种肿瘤标志物在肺癌诊断中的价值及其临床应用[J].现代肿瘤医学,2016,24(4):577-581.
[10]戎荣,程义壮,沈佐君.四种血清肿瘤标志物联合检测在肺癌诊断中的价值[J].山东医药,2018,58(1):78-80.
[2]单新洁,祁晓婷,俞荣.4项血清肿瘤标志物联合检测在肺癌中的应用价值分析[J].河北医科大学学报,2018,39(7):833-837.
[3]张海晨,王浩,宋云霄,等.多项肿瘤标志物联合检测模型在肺癌诊断中的应用价值[J].检验医学,2018,33(7):590-596.
[4]范润萍,徐笑红.NLR、LDH结合几种常见肿瘤标志物在肺癌诊断中的价值[J].中国医师杂志,2017,19(6):895-898.
[5]舒媚,吴振兴,朱振亮,等.血清肿瘤标志物联合检测在肺癌诊断中的价值[J].中华全科医学,2016,14(6):1019-1021.
[6]余洲海,孟伟.联合检测血清中四种肿瘤标志物对肺癌的诊断价值评估[J].标记免疫分析与临床,2016,23(6):655-658.
[7]刘俊,孙璀.血清肿瘤标志物单独或联合检测在原发性肺癌中的诊断价值[J].检验医学与临床,2017,14(19):2887-2889.
[8]徐一凯,陈素珍,胡丹丹,等.肿瘤标志物神经特异性烯醇化酶与糖链抗原125及血清细胞角蛋白19片段和癌胚抗原在肺癌诊断与分期中的价值[J].中国临床保健杂志,2017,20(5):498-501.
[9]杨含,罗素霞.六种肿瘤标志物在肺癌诊断中的价值及其临床应用[J].现代肿瘤医学,2016,24(4):577-581.
[10]戎荣,程义壮,沈佐君.四种血清肿瘤标志物联合检测在肺癌诊断中的价值[J].山东医药,2018,58(1):78-80.